Gentian Diagnostics ASA

Related Party Transaction • Jul 3, 2019

BECKMAN COULTER AND GENTIAN EXTEND THEIR COOPERATION IN THE EXPANDING BUSINESS IN THE FIELD OF RENAL TESTING

Moss, 03.07.2019

Gentian Diagnostics is pleased to announce the signing of a 6 year extension to the global reagent supply agreement with Beckman Coulter for the Gentian Cystatin C Immunoassay.

The companies have provided this test together globally for 10 years, with consistent sales growth. Gentian, the developer and manufacturer of the reagents, partners with Beckman Coulter for distribution of the cystatin C products to their customers for use on AU, IMMAGE, and Synchron instrumentation. Using this model, Gentian reaches a large number of laboratories globally, and Beckman Coulter is secured the delivery of a high-quality kidney function test to their customers. Such a collaboration serves the purpose of growing both companies in the area of renal testing, and patients and clinicians are offered the opportunity to the market´s most accurate kidney function assessment.

Measuring cystatin C in blood is a superior method of evaluating human kidney function, without impact from other lifestyle factors that commonly affect kidney filtration biomarkers.

Dr. Hilja Ibert, CEO of Gentian Diagnostics said: "I am very pleased to extend our partnership with Beckman Coulter. The mutual desire for signing a long- term agreement illustrates how important it is to collaborate to bring high quality diagnostic tests to a demanding and wide-spread market. Beckman Coulter is exactly the kind of partner that Gentian is set up to serve"

ABOUT GENTIAN DIAGNOSTICS AS:

Gentian Diagnostics AS is a medical diagnostics company listed on Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME". Gentian is headquartered in Moss, Norway, with a representative office in China and distribution subsidiaries in Sweden and USA. Gentian designs, develops and markets in vitro diagnostic reagents (IVD) based on its proprietary Nanosense technology. The goal is to offer efficient and accurate reagents for major clinical chemistry platforms with a focus within the areas of kidney disease, cardiac disease, inflammation and veterinary medicine. The Nanosense technology will enable users to move assays from low volume immunology platforms to fully automated, high throughput instruments with shorter turnaround times, better workflow and improved cost efficiency.

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics AS E-mail: hilja.ibert@gentian.no Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics AS E-mail: njaal.kind@gentian.no Cell Phone: +47 919 06 525